Skip to main content
Equibles
RDGL logo

RDGL · Vivos Inc · Metrics

Track RDGL — free

Use RDGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.05 +0.00 (+1.25%) At close · Sep 17
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The independent registered public accounting firm has expressed substantial doubt about the Company's ability to continue as a going concern due to limited revenue, nominal cash, and accumulated deficits since inception. Management plans to pursue additional funding through debt and equity financing (including the pending 2026 Regulation A+ Offering), enhance operating performance via strategic focus on core products, process efficiencies, and cost structure improvements. There can be no assurance of success in raising working capital or achieving profitable operations, and the financial statements include no adjustments for outcomes of this uncertainty.”
View the 10-Q filed Aug 12, 2026
Market Cap
$22.24M
Shares
494.21M

RDGL metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.05
Market cap
$22.24M

Price action

20 metrics
Price change (1W)
-2.0%
Price change (30D)
-9.5%
Price change (3M)
-22.7%
Price change (6M)
-47.6%
Price change (YTD)
-29.5%
Price change (1Y)
-48.0%
Trailing year
Price change (5Y)
-48.0%
52-week high
$0.09
52-week low
$0.05
Change from 52-week high
-48.0%
Change from 52-week low
+1.5%
Annualized volatility
87.9%
Annualized volatility (3M)
131.4%
Beta
0.2
RSI (14D)
41.1
Price vs SMA 50
-12.8%
Price vs SMA 200
-28.8%
Avg volume (3M)
1.53M
Relative volume
0.7
Average dollar volume
$96,723

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
494.21M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
224.4×
reciprocal yield 0.4%
P / book
8.1
reciprocal yield 12.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-25.9%
Operating margin
-2,852.5%
Trailing 12 months
Net margin
-3,633.6%
Gross profit (TTM)
−$25,657
Operating profit (TTM)
−$2.83M
Net income (TTM)
−$3.60M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
+142.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$99,099
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.2%
Year over year · more shares
Revenue CAGR (3Y)
+23.3%
Revenue CAGR (5Y)
+57.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-130.7%
Return on assets
-125.0%
Debt / equity
—
Current ratio
48.8
EBITDA (TTM)
−$2.54M
Free cash flow (TTM)
—
Quick ratio
47.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.27M
Total assets
$2.88M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.17M
Capital expenditures (TTM)
—
R&D (TTM)
$212,091
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
214.0%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
11 / 100

Insider activity

2 metrics
Net insider buying (90D)
$32,757
Insider-sentiment score
84 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1449349 CUSIP 92858K204 Visit website